What is a stock summary page? Click here for an overview.
Business Description
Xvivo Perfusion AB
NAICS : 334517
SIC : 3842
ISIN : SE0004840718
Compare
Compare
Traded in other countries / regions
XVIVO.Sweden0RKL.UKXVIPF.USA3XV.Germany IPO Date
2016-12-05Description
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all of the majority organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.21 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.39 | |||||
| Interest Coverage | 113.13 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 21.16 | |||||
| Beneish M-Score | -1.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 42.8 | |||||
| 3-Year EBITDA Growth Rate | 27.3 | |||||
| 3-Year EPS without NRI Growth Rate | 168.5 | |||||
| 3-Year Book Growth Rate | 16.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 28.21 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 28.61 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.53 | |||||
| 9-Day RSI | 23.51 | |||||
| 14-Day RSI | 23.54 | |||||
| 3-1 Month Momentum % | -16.29 | |||||
| 6-1 Month Momentum % | -18.26 | |||||
| 12-1 Month Momentum % | 46.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.58 | |||||
| Quick Ratio | 3.3 | |||||
| Cash Ratio | 2.34 | |||||
| Days Inventory | 313.09 | |||||
| Days Sales Outstanding | 71.07 | |||||
| Days Payable | 63.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.2 | |||||
| Shareholder Yield % | 0.79 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.95 | |||||
| Operating Margin % | 10.74 | |||||
| Net Margin % | 20.94 | |||||
| FCF Margin % | 13.53 | |||||
| ROE % | 8.43 | |||||
| ROA % | 7.55 | |||||
| ROIC % | 4.25 | |||||
| 3-Year ROIIC % | 11.44 | |||||
| ROC (Joel Greenblatt) % | 29.46 | |||||
| ROCE % | 4.19 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 47.56 | |||||
| Forward PE Ratio | 59.18 | |||||
| PE Ratio without NRI | 47.56 | |||||
| Shiller PE Ratio | 286.51 | |||||
| PS Ratio | 9.95 | |||||
| PB Ratio | 3.78 | |||||
| Price-to-Tangible-Book | 10.88 | |||||
| Price-to-Free-Cash-Flow | 73.57 | |||||
| Price-to-Operating-Cash-Flow | 73.57 | |||||
| EV-to-EBIT | 90.16 | |||||
| EV-to-Forward-EBIT | 51.08 | |||||
| EV-to-EBITDA | 90.16 | |||||
| EV-to-Forward-EBITDA | 34.91 | |||||
| EV-to-Revenue | 9.68 | |||||
| EV-to-Forward-Revenue | 8.27 | |||||
| EV-to-FCF | 70.45 | |||||
| Price-to-GF-Value | 0.51 | |||||
| Price-to-Projected-FCF | 3.77 | |||||
| Price-to-Median-PS-Value | 0.54 | |||||
| Price-to-Graham-Number | 4.79 | |||||
| Price-to-Net-Current-Asset-Value | 14.37 | |||||
| Price-to-Net-Cash | 48.11 | |||||
| Earnings Yield (Greenblatt) % | 1.11 | |||||
| FCF Yield % | 1.33 | |||||
| Forward Rate of Return (Yacktman) % | 11.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xvivo Perfusion AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 822.415 | ||
| EPS (TTM) (kr) | 5.44 | ||
| Beta | 3.16 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.34 | ||
| Volatility % | 64.04 | ||
| 14-Day RSI | 23.54 | ||
| 14-Day ATR (kr) | 17.857416 | ||
| 20-Day SMA (kr) | 335.054846 | ||
| 12-1 Month Momentum % | 46.26 | ||
| 52-Week Range (kr) | 245 - 545 | ||
| Shares Outstanding (Mil) | 31.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xvivo Perfusion AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xvivo Perfusion AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xvivo Perfusion AB Frequently Asked Questions
What is Xvivo Perfusion AB(LTS:0RKL)'s stock price today?
The current price of LTS:0RKL is kr264.61. The 52 week high of LTS:0RKL is kr545.00 and 52 week low is kr245.00.
When is next earnings date of Xvivo Perfusion AB(LTS:0RKL)?
The next earnings date of Xvivo Perfusion AB(LTS:0RKL) is 2025-04-24.
Does Xvivo Perfusion AB(LTS:0RKL) pay dividends? If so, how much?
Xvivo Perfusion AB(LTS:0RKL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers